Melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility class | Soluble in water and DMSO | Dissolves readily |
| Typical storage temperature | -20 °C or lower | Long-term, desiccated |
| Standard purity method | Reverse-phase HPLC | Area normalization |
| Freeze-thaw guidance | Limit to three cycles | Aliquot in advance |
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
=== Polymers === In polymer chemistry, MALDI can be used to determine the molar mass distribution. Polymers with polydispersity greater than 1.2 are difficult to characterize with MALDI due to the signal intensity discrimination against higher mass oligomers. A good matrix for polymers is dithranol or AgTFA. The sample must first be mixed with dithranol and the AgTFA added afterwards; otherwise the sample will precipitate out of solution.
Since the structure of asparagine was still not fully known – the location of the amine group within the molecule was still not settled – Piutti synthesized asparagine and thus published its true structure in 1888.
== Reactions and uses == Fusion of Armstrong acid in NaOH gives the disodium salt of 1,5-dihydroxynaphthalene, which can be acidified to give the diol. The intermediate in this hydrolysis, 1-hydroxynaphthalene-5-sulfonic acid, is also useful. Nitration gives nitrodisulfonic acids, which are precursors to amino derivatives. The disodium salt is sometimes used as a divalent counterion for forming salts of basic drug compounds, as an alternative to the related mesylate or tosylate salts. When used in this way such a salt is called a naphthalenedisulfonate salt, as seen with the most common salt form of the stimulant drug CFT. The disodium salt is also used as an electrolyte in certain kinds of chromatography.
Player Luke Davis gave evidence that he was instructed to keep the injections secret from Reid and other coaching staff, although other players disputed that they received such instructions. In May 2012, in a meeting of club administrators including Reid and Dank, Dank was directed to cease giving injections to players; however, evidence given by players indicated that the program was reduced rather than ceased, with many continuing to receive injections until as late as July. Evidence showed that Dank continued to liaise with sports scientists and pharmacists to seek new supplements into August; investigations later described the program as being often experimental in nature. Dank was dismissed from the club in September 2012 because he had made unauthorised expenditures, the exact nature of which was not made public. Essendon's on-field performances during the 2012 season began strongly and finished weakly, a coincidence which was later scrutinised in the context of the program. At the end of May, when the program began to be rewound, the club sat second on the ladder with an 8–1 record. The club then began to lose many players to soft tissue injuries; it won three of its next six games during the middle part of the year to drop to sixth; then lost its last seven games to finish eleventh with an 11–11 record. The CAS acknowledged these observations in its findings, noting that they carried no weight as evidence but describing them as "at least not inconsistent" with the timeline of the program.
Sources: en.wikipedia.org
== History == The U.S.-India Science & Technology Endowment Fund was established in 2009 with a joint agreement between the United States and India, having an annual budget of approximately $2 to $3 million per year. A board with members from both countries was established to award grants on a semi-annual basis. The board was established through the United States Department of State and the India Department of Science & Technology. In May 2012, then United States Secretary of State Hillary Clinton and former Indian Minister of Science and Technology Vilasrao Deshmukh awarded the first grantee of the fund. The first grantees included a partnership between both countries to develop a cold chain storage for produce, a procedure for metabolic screening of newborns, and a shoe specifically built to assist patients with Parkinson's disease.
==== The "disorganized crime" and choice theses ==== One of the most important trends to emerge in criminological thinking about OC in recent years is the suggestion that it is not, in a formal sense, "organized" at all. Evidence includes lack of centralized control, absence of formal lines of communication, fragmented organizational structure. It is distinctively disorganized. For example, Seattle's crime network in the 1970s and 80s consisted of groups of businessmen, politicians and of law enforcement officers. They all had links to a national network via Meyer Lansky, who was powerful, but there was no evidence that Lansky or anyone else exercised centralized control over them. While some crime involved well-known criminal hierarchies in the city, criminal activity was not subject to central management by these hierarchies nor by other controlling groups, nor were activities limited to a finite number of objectives. The networks of criminals involved with the crimes did not exhibit organizational cohesion. Too much emphasis had been placed on the Mafia as controlling OC. The Mafia were certainly powerful but they "were part of a heterogeneous underworld, a network characterized by complex webs of relationships." OC groups were violent and aimed at making money but because of the lack of structure and fragmentation of objectives, they were "disorganized". Further studies showed neither bureaucracy nor kinship groups are the primary structure of organized crime; rather, the primary structures were found to lie in partnerships or a series of joint business ventures.
=== Basic research and translational preclinical animal model research === Jennette, in collaboration with Falk, and UNC faculty associates Hong Xiao and Peiqi Hu, and other faculty and trainees, made multiple discoveries about the cellular and molecular mechanisms that cause ANCA disease. He, Falk, and their research associates published the first demonstration that ANCA can activate neutrophils in vitro, and the first in vivo animal model confirming that ANCA antibodies cause glomerulonephritis by inducing glomerulonephritis and vasculitis in mice by intravenous injection of anti-MPO antibodies. This model has been used to make discoveries about the pathogenesis of ANCA disease, including the discovery of a key role for alternative complement pathway activation and C5a receptor engagement, which can be targeted by a novel small molecular inhibitor of C5a receptor (Avacopan). This approach to therapy was FDA-approved for patient care in 2021.
The mass-to-charge ratio (m/Q) is a physical quantity relating the mass (quantity of matter) and the electric charge of a given particle, expressed in units of kilograms per coulomb (kg/C). It is most widely used in the electrodynamics of charged particles, e.g. in electron optics and ion optics. It appears in the scientific fields of electron microscopy, cathode ray tubes, accelerator physics, nuclear physics, Auger electron spectroscopy, cosmology and mass spectrometry. The importance of the mass-to-charge ratio, according to classical electrodynamics, is that two particles with the same mass-to-charge ratio move in the same path in a vacuum, when subjected to the same electric and magnetic fields. Some disciplines use the charge-to-mass ratio (Q/m) instead, which is the multiplicative inverse of the mass-to-charge ratio. The CODATA recommended value for an electron is Q/m = −1.75882000838(55)×1011 C⋅kg−1.
Topical hydrocortisone is formulated as liquid, solution, lotion, cream, gel, ointment, foam, and spray. The strength of topical hydrocortisone products ranges from 0.1% to 2.5%, which means there could be 1 mg to 25 mg hydrocortisone in 1g of the products. Some formulations for topical hydrocortisone include hydrocortisone 0.5% cream or ointment, hydrocortisone 1% cream or ointment, and hydrocortisone 2.5% cream or ointment. Regarding the method of applying the medications, please refer to the package insert or consult a pharmacist. Some less common forms of topical hydrocortisone are also available in the market. For example, hydrocortisone butyrate is a relatively potent topical hydrocortisone cream that can only be purchased when you have a valid prescription. Besides, some forms of topical hydrocortisone are mixed with antimicrobial drugs to treat bacterial or fungal problems of the skin.
Sources: en.wikipedia.org
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.
Repeated freeze-thaw cycles, alkaline pH, and exposure to light or oxygen are the main drivers. Moisture uptake by the solid also matters.
Mass spectrometry provides the strongest single identity check by matching the observed molecular ion to the expected value. Chromatographic retention time alone is not sufficient.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.